Arca up as Novartis buys early-stage asset
This article was originally published in Scrip
Executive Summary
Arca Biopharma has entered into an agreement whereby Novartis is acquiring global patent rights to an undisclosed molecular target in an undisclosed therapeutic area – one of Arca's early-stage assets that is outside of the company's core focus area of cardiovascular disease.